Skip to Content

'
John F. DeGroot, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Neuro-Oncology, Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Director, Neuro-Oncology Fellowship Program, Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1998 University of Texas Medical Branch at Galveston, Galveston, TX, MD, Honors, Medicine
1992 Stanford University, Stanford, CA, BA, Human Biology

Postgraduate Training

7/2002-6/2004 Clinical Fellowship, Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
7/1999-6/2002 Clinical Residency, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
7/1998-6/1999 Clinical Internship, Neurology, Johns Hopkins Bayview Medical Center, Baltimore, MD

Board Certifications

5/2003 American Board of Psychiatry and Neurology

Selected Publications

Peer-Reviewed Original Research Articles
1. de Groot J, Piao Y, Lu L. AMPA receptors promote perivascular glioma invasion via (beta) 1 integrin-dependent adhesion to the extracellular matrix. Neuro-Oncology 11(3):260-73, 6/2009. PMID: 18957620.
2. de Groot JF, Milano V. Improving the Prognosis for Patients with Glioblastoma: The Rationale for Targeting Src. J Neuro-Oncology, 5/2009. PMID: 19436954.
3. Milano V, Piao Y, Lafortune T, de Groot J. Desatinib-induced autophagy is enhaced in combination with temozolomide in glioma. Molecular Cancer Therapy 8(2):394-406, 2/2009. PMID: 19190119.
4. Gonzales J, de Groot J. Combination therapy for malignant glioma based on PTEN status. Expert Rev Anticancer Therapy 8(11):1767-1779, 11/2008. PMID: 18983237.
5. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neuro-Oncology 90(1):89-97, 10/2008. PMID: 18581057.
6. de Groot, WKA Yung. Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas. Cancer J 14(5):279-285, Sep-Oct, 2008. PMID: 18836331.
7. Gomez-Manzano C, Holash J, Fueyo J, Xu Jing, Conrad, CA, Aldape KD, DeGroot JF, Bekele N, Yung WKA. VEGF Trap induces antiglioma effect at different stages of disease. Neuro-Oncology 10(6):940-945, 2008. PMID: 18708344.
8. de Groot JF, Liu TJ, Fuller G, Yung WK. The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res 65(5):1934-40, 2005. PMID: 15753393.

Grant & Contract Support

Title: SPORE in Brain Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 7/1/2008 - 6/30/2013
 
Title: Predictors of Glioblastoma Response to VEGF Trap
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2008 - 7/1/2011
 
Title: The Role of AMPA Receptors in Glioma Proliferation and Invasion
Funding Source: UTMDACC Institutional Research Grant-IRG
Role: Principal Investigator
Duration: 2/1/2008 - 1/31/2010
 
Title: Correlative Markers of Glioblastoma Response to VEGF Trap
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/2007 - 11/2009
 
Title: Deciphering Synergistic Combinatorial Targets in Glioma
Funding Source: NIH/NCI/NINDS
Role: Co-Investigator
Duration: 9/2006 - 6/2011

Last updated: 9/11/2009